Cerebrolysin
FPF 1070, Cerebrolysatum, porcine brain hydrolysate
The Ground Truth Score
four plain questions, never one numberPorcine brain extract with real RCT data in stroke and TBI, but evidence is thin for healthy-brain cognitive enhancement.
Bottom line
Cerebrolysin is a complex mixture of low-molecular-weight neuropeptides from porcine brain tissue, approved in 45+ countries for stroke and dementia, with multiple RCTs showing modest functional benefit in neurological injury, but the evidence for healthy-individual cognition is essentially zero and the Cochrane review called overall certainty low to very low.
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓5-10 mL IM daily x 10-21 days, cycled 2-4x/year; clinical trials used 15-30 mL IV; no SubQ standard exists
Reported, not prescribed. Verify your vial and your math.
The gist
- Real RCT data in stroke and TBI, but the primary functional independence endpoint did not reach significance and NIHSS improvement (1.39 points) sits below the clinically meaningful threshold.
- The nootropic community uses it off-label for cognitive enhancement in healthy brains. Zero controlled evidence exists for that population.
- The preclinical mechanistic foundation has a serious problem: multiple core papers were retracted in 2025 after NIH confirmed the lead researcher (Eliezer Masliah) fabricated data, and he was funded by the manufacturer.
First documented human use
1954, initial clinical approval in Austria for metabolic brain failure and TBI by EVER Neuro Pharma (formerly EBEWE)
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. I grade each one below.
- Marketed as a neurotrophic factor mimetic that crosses the blood-brain barrier
- Claimed to promote neuroplasticity and axonal sprouting after brain injury
- Sold as a cognitive enhancer for healthy users at low IM doses
- Promoted for Alzheimer's and vascular dementia as a disease-modifying adjunct
- Claimed to reduce neuroinflammation and apoptosis via BDNF/NGF pathway activation
The data behind each bullet
What actually backs it
Improves functional recovery after acute ischemic stroke
Meta-analysis of 14 RCTs (N=2,884) showed pooled NIHSS improvement of 1.39 points (95% CI 0.53-2.25). However, the primary functional independence endpoint (mRS 0-2) did NOT reach statistical significance (RR 1.31, 95% CI 0.90-1.91, p>0.05). The NIHSS minimum clinically important difference is typically defined as 4+ points by NINDS standards, so 1.39 points is sub-threshold for clinical meaningfulness at the individual level. Most trials were industry-funded.
PMC12465088 - Safety and Efficacy of Cerebrolysin for Neurorecovery After Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of 14 Randomized Controlled Trials (2025) ↗Improves outcomes in traumatic brain injury
2023 systematic review of 10 clinical studies (N=8,749) found statistically significant improvement in GCS and GOS scores. Mortality and length of stay were not affected. Multiple industry-sponsored trials limit certainty. Important limitation: only a subset of the 10 studies were blinded RCTs; the remainder were retrospective observational studies. The pooled N reflects the mixed design, not an RCT-only sample, which makes the B grade a ceiling rather than a floor for this claim.
PMC10046100 - Cerebrolysin in TBI: Systematic Review and Meta-Analysis, Brain Sciences 2023 ↗Benefits Alzheimer's disease and vascular dementia
Cochrane review for vascular dementia (2019, 6 RCTs, N=597) found promising signals but rated evidence quality as low to very low. A 2023 Cochrane update on cerebrolysin for acute ischaemic stroke (pub7, CD007026) found no evidence of benefit on all-cause death and confirmed that the safety profile is population-dependent. Separately, the 2023 Cochrane stroke update and prior dementia evidence together document a statistically significant increase in non-fatal serious adverse events in the cerebrolysin group in dementia populations (RR 2.39, 95% CI 1.10-5.23; 3 trials, N=1,335), with the 30 mL/10-day dose reaching RR 2.87 (95% CI 1.24-6.69). This SAE signal is incompatible with any confidence of benefit in this population.
Cochrane Library - Cerebrolysin for Vascular Dementia, Cui 2019 (PMID 31710397) ↗Reduces microglial activation and neuroinflammation
In vitro and animal data support anti-inflammatory and neuroprotective effects via BDNF/NGF receptor mimicry. Mechanistic plausibility is established; direct causal evidence in humans is not. Note: this study originates from the EuroEspes Biomedical Research Center (Alvarez XA, Cacabelos R, et al.), a lab with documented ties to EVER Pharma (the cerebrolysin manufacturer) and co-author networks with research integrity concerns. The study itself has not been retracted, but its institutional provenance and funder proximity should be weighed when using it as a mechanistic anchor.
PubMed 10961440 - Cerebrolysin reduces microglial activation in vivo and in vitro (Alvarez et al., EuroEspes Biomedical Research Center, 2000) ↗Safe with adverse event profile similar to placebo in controlled trials
Meta-analysis of 12 RCTs (N=2,202) found no statistically significant difference in adverse events vs. placebo in stroke trials. However, this safety finding is population-specific: a 2023 Cochrane update found a statistically significant increase in non-fatal serious adverse events in dementia populations (RR 2.39, 95% CI 1.10-5.23), rising to RR 2.87 at 30 mL/10-day dosing. The B-level safety finding for stroke patients should not be generalized to dementia or healthy populations. Absolute contraindications include epilepsy and porcine allergy. Rare seizure reports exist, causality not established.
PMC8708612 - Safety Meta-Analysis 12 RCTs (stroke population only), 2021 ↗Mechanism
How it's assumed to work
Assumed · theoretical pathway
Assumed (mechanistic plausibility, not proven causal chain in humans). Cerebrolysin contains low-molecular-weight peptide fragments (all under 10 kDa) that are proposed to cross the blood-brain barrier and mimic endogenous neurotrophic factors including BDNF, NGF, GDNF, and CNTF. Proposed downstream effects include activation of TrkB and TrkA receptors, PI3K/Akt and MAPK/ERK pathway signaling, inhibition of caspase-3 (apoptosis), upregulation of Bcl-2 (anti-apoptotic), and reduction of microglial activation. Whether these mechanisms are operative in healthy brains at community-level doses is not established. Caution: a substantial portion of the preclinical mechanistic evidence was produced by Eliezer Masliah and Hari Shanker Sharma, both of whom have papers under active retraction and data integrity review as of 2025.
Dosing & handling
What users and clinicians report
Community-reported range: 5-10 mL IM (intramuscular) daily for 10-20 day courses, repeated 2-4x per year. Clinical trials used 30 mL IV infusion daily for 10-21 days in stroke/TBI. Some nootropic users report 2-5 mL SC (subcutaneous) though SC is not a studied route.
Reported doses are from community use, not prescriptions. The biggest dosing risk is route confusion: doses above 10 mL require IV infusion diluted in saline over 15-60 minutes. Self-administering IV infusions outside a clinical setting carries risk of air embolism, phlebitis, and severe allergic reaction with no immediate medical response available. Gray-market vials have no manufacturing quality guarantee.
Timing & food
Clinical trials administered IV infusions daily in the morning over 10-21 day blocks. No pharmacokinetic basis exists for specific timing in healthy-user protocols. Community practice varies widely (morning only, split AM/PM) without evidence basis.
Half-life
Not well characterized in humans. The peptide mixture is heterogeneous; individual fragments likely have half-lives ranging from minutes to a few hours. IV infusion achieves peak CNS levels during administration; IM half-life estimates are extrapolated, not directly measured.
Reconstitution sensitivity
Not reconstituted. Cerebrolysin is supplied as a ready-to-use aqueous solution (1 mL, 2 mL, 5 mL, 10 mL, 20 mL ampoules at 215.2 mg/mL). Requires refrigeration (2-8 degrees C). Gray-market sources may have cold-chain gaps that degrade the peptide mixture.
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
High volume of community reports, primarily from Eastern European and Russian nootropic communities where Cerebrolysin is legally available and inexpensive. Growing Western nootropic interest since 2020.
Consistency
Mixed. Subjective reports of improved focus, mood, and verbal fluency are common but inconsistent. A subset reports agitation, headache, and no noticeable effect. TBI/stroke recovery anecdotes tend to be more positive and consistent than healthy-user reports.
Source credibility
Low for healthy-user enhancement claims. The community signal reflects a drug being used far outside its studied population (acute neurological injury) at doses below clinical trials. Hard to separate from expectation effects.
- Anecdote: Eastern European and Russian users report improved verbal fluency and recall after 10-day IV courses, often at clinical doses (10-20 mL); effect described as arriving 2-3 days into the course and fading within 4-6 weeks post-cycle
- Anecdote: A subset of users report agitation, irritability, and disrupted sleep during the active dosing window, especially at higher doses, consistent with the neurostimulatory profile seen in trials
- Anecdote: Nootropic community users doing IM self-injection at 5 mL report subtler effects than IV users, with some reporting no noticeable change; the IV-vs-IM gap in perceived effect is a recurring theme
- Anecdote: TBI and post-concussion users report the most consistent and pronounced subjective benefit; healthy-brain users are the most split, with a vocal minority reporting nothing and attributing prior reports to placebo
Placebo risk, High
Most wellness and cognitive enhancement endpoints are subjective (focus, mental clarity, mood). The ritual of IV or IM injection and the drug's exotic porcine-brain origin create strong expectation effects. Clinical trials in stroke/TBI used objective functional scales (NIHSS, GCS, GOS), which are absent in self-experimenter use.
Risk panel
What could go wrong
Adverse events
Generally mild in acute stroke controlled trials. Most common: dizziness, agitation, feeling hot, injection site reactions, mild headache, nausea. Adverse event incidence statistically similar to placebo in stroke meta-analyses (N=2,202). Critical population-specific warning: the 2023 Cochrane data in dementia populations found a statistically significant ~2.4x increase in non-fatal serious adverse events (RR 2.39, 95% CI 1.10-5.23; 3 trials, N=1,335), with the 30 mL/10-day protocol showing RR 2.87. The safety profile cannot be uniformly assumed across populations.
Theoretical concerns
Porcine-derived proteins carry a theoretical prion contamination risk, though manufacturing processes (enzymatic hydrolysis + filtration) are designed to eliminate this. Seizure threshold lowering is a documented concern.
Contraindications
Absolute: epilepsy or history of grand mal convulsions (may increase seizure frequency), porcine allergy, severe renal impairment. Not recommended in pregnancy. The 2023 Cochrane data in dementia populations documents a statistically significant increase in non-fatal serious adverse events that is absent from the stroke population, meaning dementia patients should be considered a distinct and higher-risk group.
Honest unknowns
Long-term effects of repeated cycling in healthy individuals are unstudied. The complex mixture contains hundreds of uncharacterized peptide fragments; batch variation between manufacturers (especially gray-market sources) is a real concern. No human pharmacokinetic data on IM vs. IV bioavailability equivalence.
Confound watch
Heavily stacked in nootropic communities with racetams, semax, selank, and other neuropeptides, making attribution impossible. Many users are also on TRT or GLP-1 agonists; improved cognitive clarity on either of those baselines is commonly misattributed to Cerebrolysin. Clinical trial benefits occurred in acute injury patients, not healthy individuals.
History
Discovery → first use → status
- 1949Developed by Professor Eberhard Windisch at the University of Vienna as a porcine brain-derived extract for treating TBI and metabolic brain failure in post-war Austria
- 1954First approved for clinical use in Austria; EBEWE (later EVER Neuro Pharma) industrialized production in the 1970s and standardized batch-to-batch consistency
- 1980s-1990sGained regulatory approval across Russia, Eastern Europe, China, and Asian nations; now approved in 45+ countries for stroke, TBI, and dementia
- 2019Cochrane review on vascular dementia described evidence as promising but low-certainty; FDA never approved it for any indication in the US, though orphan drug designation was granted for frontotemporal dementia investigation
- 2023-2025NIH found that Eliezer Masliah, former head of the Division of Neuroscience at the National Institute on Aging, committed research misconduct (data fabrication and falsification) across 130+ papers published 1997-2023. Masliah received EVER Pharma funding for multiple cerebrolysin studies and co-authored with Herbert Moessler (former EVER Pharma general manager, 19 papers flagged). Multiple cerebrolysin preclinical papers by Masliah and collaborator Hari Shanker Sharma were retracted by 2025, including a BMC Neuroscience paper on Pick's disease (retraction note PMID 40065222). The scope of affected preclinical cerebrolysin literature is actively under review as of 2025.
Verification
The COA standard, applied
Grade adversarially re-reviewed 2026-06-21 and downgraded to reflect the absence of formal human safety/efficacy data. Citations corrected 2026-06-22: (1) stroke claim basis updated to disclose that the mRS functional independence primary endpoint did not reach significance (RR 1.31, p>0.05) and that NIHSS 1.39 points is sub-threshold for NINDS MCID; (2) TBI claim basis updated to disclose mixed RCT/observational study design; (3) safety claim downgraded from B to C and split to reflect population-specific SAE finding in dementia cohorts (Cochrane RR 2.39); (4) microglial citation updated to disclose EuroEspes/EVER Pharma institutional ties; (5) research integrity disclosure added to risk section and mechanism section covering Masliah/Sharma misconduct and EVER Pharma funding; (6) 2023-2025 research misconduct history entry added; (7) 2023 Cochrane ischaemic stroke update and For Better Science/BMC retraction notice added to verification sources.
The full verification standard →Sources
Where this comes from
- PMC12465088 - Safety and Efficacy of Cerebrolysin for Neurorecovery After Acute Ischemic Stroke: 14 RCT Meta-Analysis (2025) ↗· Most comprehensive stroke meta-analysis available as of 2025; pooled N=2,884; NIHSS improvement 1.39 points (significant); mRS 0-2 functional independence RR 1.31 (NOT significant, p>0.05); notes industry funding limitations. NIHSS improvement is sub-threshold for NINDS MCID of 4+ points.
- Cochrane Library - Cerebrolysin for Vascular Dementia (Cui 2019, PMID 31710397) ↗· Cochrane systematic review; low to very low certainty overall; 6 RCTs N=597; major concerns about industry funding and study heterogeneity
- PMC10046100 - Cerebrolysin in TBI: Systematic Review and Meta-Analysis (2023) ↗· 10 clinical studies (prospective and retrospective mixed design, not all blinded RCTs) N=8,749; significant GCS/GOS improvement; mortality not affected. Mixed study design should be weighted when interpreting pooled results.
- PMC8708612 - Safety of Cerebrolysin for Ischemic Stroke: 12 RCT Meta-Analysis (2021) ↗· Safety-focused meta-analysis N=2,202 stroke patients; adverse events not significantly different from placebo in this population. Does not cover dementia or healthy-user populations where a separate Cochrane update found increased serious adverse events.
- Cochrane Library - Cerebrolysin for Acute Ischaemic Stroke, Ziganshina 2023 (CD007026.pub7) ↗· 2023 Cochrane update; no evidence of mortality benefit; confirms the population-specific safety divergence between stroke and dementia cohorts.
- For Better Science - Cerebrolysin: Sharmas, Masliah, and EVER Pharma (October 2024) ↗· Investigative documentation of research misconduct findings, EVER Pharma funding ties, and the scope of cerebrolysin preclinical papers affected by the Masliah/Sharma data integrity crisis.
- BMC Neuroscience Retraction - Cerebrolysin Pick's disease paper (Masliah et al., PMID 40065222) ↗· Retraction notice for a cerebrolysin preclinical paper retracted in 2025 due to fabricated/re-used figure panels. One of multiple Masliah cerebrolysin retractions.
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.